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Background. The Cryptococcus neoformans polysaccharide capsule is a well-characterized virulence factor with
immunomodulatory properties. The organism and/or shed capsule is postulated to raise intracranial pressure (ICP)
in cryptococcal meningitis (CM) by mechanical obstruction of cerebrospinal ﬂuid (CSF) outﬂow. Little is known re-
garding capsule phenotype in human cryptococcosis. We investigated the relationship of ex vivo CSF capsular phe-
notype with ICP and CSF immune response, as well as in vitro phenotype.
Methods. In total, 134 human immunodeﬁciency virus (HIV)-infected Ugandan adults with CM had serial
lumbar punctures with measurement of CSF opening pressures, quantitative cultures, ex vivo capsule size and shed-
ding, viscosity, and CSF cytokines; 108 had complete data. Induced capsular size and shedding were measured in
vitro for 48 C. neoformans isolates.
Results. Cryptococcal strains producing larger ex vivo capsules in the baseline (pretreatment) CSF correlated
with higher ICP (P = .02), slower rate of fungal clearance (P = .02), and paucity of CSF inﬂammation, including de-
creased CSF white blood cell (WBC) count (P < .001), interleukin (IL)-4 (P = .02), IL-6 (P = .01), IL-7 (P = .04), IL-8
(P = .03), and interferon γ (P = .03). CSF capsule shedding did not correlate with ICP. On multivariable analysis,
capsule size remained independently associated with ICP. Ex vivo capsular size and shedding did not correlate with
that of the same isolates grown in vitro.
Conclusions. Cryptococcal capsule size ex vivo is an important contributor to virulence in human cryptococcal
meningitis.
Keywords. Cryptococcus neoformans; cryptococcal meningitis; HIV; polysaccharide capsule; intracranial pres-
sure; immune response; CSF; human.
Cryptococcus neoformans, an opportunistic fungus
causing infection in immunocompromised hosts, is the
most common cause of adult meningitis in Sub-
Saharan Africa [1, 2] and a major cause of infectious
mortality [3]. A distinctive diagnostic feature of C. neo-
formans in cerebrospinal ﬂuid (CSF), as well as its most
important virulence factor [4], is its polysaccharide
capsule. The capsule is composed of branching polysac-
charide ﬁbers of glucuronoxylomannan (GXM, 90%–
95%of capsularmass), andgalactoxylomannan(GalXM)
[5], whose highly dynamic biophysical and chemical
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structure confers phenotypic diversity, facilitating immune
evasion and survival within the host [6].
During mammalian infection, the capsule undergoes dra-
matic changes in size, structure, and proportion relative to total
cell volume, stimulated by factors such as iron limitation and
physiologic CO2 [7, 8]. Shed GXM polysaccharide, commonly
known as cryptococcal antigen (CrAg), has a large molecular
weight and is viscous in solution [9], which may contribute to
increased intracranial pressure (ICP), especially in the setting
of a large fungal burden [10], by mechanically obstructing CSF
outﬂow through arachnoid villi [11].
Many studies demonstrating the importance of the C. neofor-
mans capsule in virulence have used laboratory strains in
animal models. In an immunocompetent murine model, acap-
sular mutants were avirulent [12, 13]. In one murine study
using clinical isolates from AIDS patients, capsule size within
mouse brains correlated with virulence [14]. The capsule and
actively shed GXM have deleterious effects on the immune re-
sponse, including inhibiting phagocytosis, T-cell proliferation,
and proinﬂammatory cytokine production [6]. A mucoid phe-
notypic switch variant (MC) of a serotype D strain produces
larger capsules, associated with greater tissue shedding of more
viscous GXM compared to the smooth variant (SM). MC
elicits a more vigorous yet ineffective inﬂammatory response,
exhibiting enhanced virulence in mice [15], and showed greater
propensity than SM to cause raised ICP in a rat model [16].
The cryptococcal capsule has not been well characterized in
vivo in human infection. Our study’s objective was to test the
hypothesis that diversity in the C. neoformans capsular pheno-
type in human cryptococcal meningitis (CM) is associated with
the propensity to develop raised ICP and capacity to elicit a
CSF inﬂammatory response. Given in vitro capsular phenotype
is often assumed to represent in vivo phenotype, our second
objective was to correlate ex vivo phenotype in human CSF
with in vitro phenotype of corresponding clinical isolates
grown in culture.
Using serial CSF samples and clinical isolates collected and
examined prospectively in an African clinical trial cohort, we
present the ﬁrst study to describe the relationship between ex
vivo C neoformans capsular phenotype and clinical and
immune parameters in the human host.
METHODS
Study Population
Specimens were collected from a prospective cohort at Mulago
Hospital, Kampala, Uganda, as a nested sub-study of the Cryp-
tococcal Optimal ART Timing (COAT) trial (clinicaltrials.gov:
NCT01075152). Inclusion criteria were human immunodeﬁ-
ciency virus (HIV)-infected, ART-naive persons ≥18 years pre-
senting with a ﬁrst CM episode conﬁrmed by CSF culture and/
or CrAg testing. Written informed consent was provided.
Participants had serial lumbar punctures (LPs) on days 1, 7,
and 14 of treatment with amphotericin B deoxycholate (0.7–
1.0 mg/kg/day) and ﬂuconazole (800 mg/day). CSF opening
pressure (OP) was measured at each LP, up to 55 cm H2O. The
trial had approval from the Research Ethics Committees of
Makerere University, University of Minnesota, Mulago Hospi-
tal, and Uganda National Council for Science and Technology.
Sample Collection and Storage
CSF supernatants and cryptococcal isolates (taken as a sweep
across multiple colonies) were cryopreserved at −80°C prior to
shipment to St. George’s University, London (SGUL). C. neo-
formans were routinely grown at 37°C on either Sabouraud dex-
trose agar (SDA), or in Sabouraud dextrose broth (SDB) with
shaking at 150 rpm, unless otherwise speciﬁed.
Whole CSF Microscopy and Quantitative Cultures
Quantitative cultures were performed by serial 10-fold dilution
(up to 1:105), and 100 μL of each dilution inoculated onto SDA.
Plates were incubated at 30°C for ≤14 days, and colonies
counted at the lowest dilution showing discernible colonies,
multiplying by the dilution to give colony-forming units (CFU)
per mL CSF. Rate of clearance of infection, or early fungicidal
activity (EFA), was determined by subject-speciﬁc linear regres-
sion of log10-transformed serial cultures by day of cryptococcal
therapy, as described elsewhere [17, 18].
CSF Supernatant CrAg and Cytokine Analysis
Whole CSF was centrifuged for 10 minutes at 3500 g, superna-
tant stored and shipped at −80°C to Minnesota. CrAg titers
were determined using the CrAg Lateral Flow Assay (Immy,
Oklahoma) semi-quantitatively, by performance of serial 2-fold
dilutions of CSF, starting at 1:250. CSF cytokines were mea-
sured via Luminex (Bio-Rad, Hercules, CA) for interleukin 1β,
interleukin 2, interleukin 4 (IL-4), interleukin 5, interleukin 6
(IL-6), interleukin 7 (IL-7), interleukin 8 (IL-8), interleukin 10,
interleukin 12, interleukin 13, interleukin 17, granulocyte
colony-stimulating factor, granulocyte macrophage colony-
stimulating factor, interferon γ (IFN-γ), macrophage chemoat-
tractant protein 1, macrophage inﬂammatory protein 1β ,
tumor necrosis factor α (TNF-α), and vascular endothelial
growth factor (VEGF).
Capsule Size Measurements
For ex vivo analysis fresh CSF was counter-stained with India
ink, and capsule thickness ([total diameter - cell body diame-
ter]/2), hereafter referred to as capsule size, measured within 1
hour of LP, using a 40× objective and an eyepiece grid micro-
meter (Wirsam Scientiﬁc, Cape Town). Digital photography
via microscope C-mount documented views for external
quality assurance.
For in vitro analysis, C. neoformans isolates were grown over-
night in SDB. The following day 20 μL of culture was inoculated
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into 5 mL capsule-inducing media (Dulbecco’s Modiﬁed Eagle
Medium with 1% NCTC, 10% heat-inactivated fetal bovine
serum) and incubated at 37°C with 10% CO2 for 48 hours.
Cells were harvested by centrifugation at 950 × g for 5 minutes,
counter-stained with India ink, imaged using 40× objective,
and measured using ImageJ software (v1.44o). Mean capsular
parameters were measured for 30–50 cells ex vivo and 50 cells
in vitro.
Cryptococcal Capsule Glucuronoxylomannan (GXM) Shedding
in In Vitro Culture Supernatants and Ex Vivo CSF
Cryptococcus neoformans isolates were inoculated into 10 mL
SDB, grown at 37°C until optical density (OD)600 was 0.7–1.1
and centrifuged twice at 950 g for 5 minutes. Supernatants were
maintained at 4°C short-term or −80°C long-term. GXM con-
centration was determined on in vitro culture supernatants and
corresponding patient CSF supernatants using the CrAg EIA
(IMMY, Oklahoma). Brieﬂy, 50 μL of specimen was added to
96-well plates coated with anti-GXM monoclonal antibody.
Using specimen diluent, whole CSF was diluted 1:10, and
culture supernatants diluted 1:100 and titrated using 1:5 dilu-
tions. A positive control of 10 ng/mL cryptococcal serotype A
GXM was included (all isolates tested were conﬁrmed serotype
A by polymerase chain reaction). EIA titers were calculated
using the highest 450 nm absorbance value falling within the
acceptable range (0.265–2.55). Final GXM concentration was
determined by comparison of OD450 against the positive
control. For comparison of in vitro-in vivo shedding, in vitro
titers were normalized to OD600 of 1, and CSF titers normalized
to a CSF fungal burden of 1 log10CFU/mL.
GXM Production and Puriﬁcation
GXM puriﬁcation was performed as described elsewhere [19].
Brieﬂy C. neoformans isolates were inoculated into 10 mL SDB
and incubated overnight at 30°C. Cultures were added to 500
mL minimal media (10 mM MgSO4, 29.3 mM KH2PO4, 13
mM glycine, 3 μM thiamine-HCl, pH 5.5 with 15 mM glucose),
and incubated for 11 days at 30°C with shaking. Cultures were
centrifuged at 4000 g for 15 minutes (at 4°C), supernatant
removed, and centrifuged again at 15 000 g for 15 minutes
(4°C). Supernatant was passed through a 0.22 μM Millipore
vacuum ﬁlter and concentrated using an Amicon ﬁlter (100
kDa cut-off ). The GXM “jelly” was removed from the mem-
brane and lyophilized in preparation for viscosity measure-
ments.
Viscosity Measurements
Viscoelastic properties of CSF supernatants and GXM solutions
were measured using 2 microrheology techniques: passive
video particle tracking and optical tweezers. The ﬁrst was per-
formed using an upright BH2 microscope (Olympus, Melville,
New York) equipped with a Prosilica GV640M complemen-
tary metal-oxide semiconductor camera and 100× objective.
Carboxylic-acid-modiﬁed polystyrene spheres (1 μm) were
used as probes. Images were stored as AVI ﬁles (25 frames/sec).
An average 30 particles per frame were tracked simultaneously
in 10 minute movies, which were processed using a particle-
tracking MATLAB code (University of Glasgow). CSF superna-
tant viscosity was measured by mean square displacement
kDr2ðtÞl ; k½rðt þ tÞ  rðtÞ2l of the probes’ trajectories r(t),
using the formula:
kDr2ðtÞl ¼ kBT
pah
t
where kBT is thermal energy, τ is lag-time (or time interval), a
is particle radius, and η ﬂuid viscosity.
Microrheology measurements with optical tweezers were
performed on puriﬁed GXM dissolved in ultrapure H2O (con-
centration range 10−3 mg/mL–10 mg/mL). Viscoelastic proper-
ties of GXM solutions were measured using both the analytical
method and the optical tweezers setup described in Tassieri
et al [20]. The linear viscoelastic properties of the solutions can
be represented by the frequency-dependent complex shear
modulus GðvÞ ¼ G0ðvÞ þ iG00ðvÞ, a complex number provid-
ing information on both the elastic (G0ðvÞ) and viscous
(G00ðvÞ) nature of the ﬂuid. The complex modulus can be ex-
pressed as a function of the normalized position autocorrela-
tion function AðtÞ ¼ k~rðtÞ~rðt þ tÞl=kr2l [21]:
GðvÞ ¼ k
6pa
1
ivA^ðvÞ  1
 !1
where k is trap stiffness and A^ðvÞ is the Fourier transform of
AðtÞ. For this experiment, the viscosities of GXM solutions
were evaluated as the value of GðvÞ=v for v ¼ 1 rad/s.
Statistical Analysis
Data were analyzed using SAS version 9.3 (SAS Institute, North
Carolina) and Stata v11 (Statacorp, Texas). Correlations were
assessed with Spearman rank correlation (ρ), categorical compar-
isons used the χ2 test, and continuous used the Kruskal-Wallis
test. Linear regression was used to estimate the relationship of
capsule size with EFA and CSF opening pressure. All CSF pa-
rameters signiﬁcantly associated with CSF OP on univariate
linear regression analysis (P≤ .05), were combined into a mul-
tivariable model to investigate factors independently associated
with ICP. Despite lack of signiﬁcant univariate association in
this study, baseline CSF fungal burden was also included in the
multivariable model due to its previously described association
with ICP [10]. Changes in cell body and capsule size during an-
tifungal therapy were assessed using mixed effects modeling
with a random term accounting for inter-person correlation
over time.
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RESULTS
Among 134 HIV-infected persons with CM, 362 serial LPs
were performed. At the baseline diagnostic LP, prior to antifun-
gal therapy, 124 persons had CSF OP recorded and 122 persons
had capsular parameters measured in real-time on fresh CSF.
Complete data were available for 108 persons for capsule size,
LP OP, and CSF cytokines. Table 1 shows baseline clinical vari-
ables and CSF parameters. Clinical parameters were character-
istic of HIV-infected persons presenting with CM in Africa:
median age 35 years, median CD4 count 16 cells/μL, high CSF
fungal burden (median 5.1 log10 CFU/mL), and minimal CSF
inﬂammation (median 10 lymphocytes/μL CSF).
Using intra-subject mean capsule size, the median (IQR) ex
vivo capsular size for the cohort was 5.3 (4.6–6.3) μm, with
capsule comprising almost two-thirds (65%) of total cell diam-
eter. Quantiﬁcation of baseline CSF GXM and GXM shedding
of its corresponding C. neoformans isolate in vitro was per-
formed on the ﬁrst 38 participants. In CSF, median (IQR)
GXM concentration was 4.8 (1.28–16.27) μg/mL. Using CrAg
lateral ﬂow assay (LFA) titers (n = 119) as a semi-quantitative
measure of capsular shedding into CSF, mean capsule size
correlated with CrAg shedding (r = 0.27, P = .005), including
after adjustment for fungal burden (multivariable regression,
P = 0.024).
CSF viscosity was measured in a total of 38 samples, of
which 15 were at baseline. Median viscosity relative to water
was 1.1. CSF viscosity in baseline and serial CSF samples corre-
lated with fungal burden (r = 0.52, P < .001) and ex vivo GXM
shedding (r = 0.72, P = .003) but not with CSF protein (r = 0.1,
P = .6).
Strains Producing Larger Cells and Capsules are Associated
With Higher Opening Pressure
Average baseline CSF capsule size correlated with baseline CSF
OP (r = 0.22, P = .02). By stratifying the cohort into OP catego-
ries, it became apparent that this effect was particularly driven
by the patients with extremely high OP >40 cm H2O (Figure 1).
The correlation between total cell diameter and baseline
opening OP was of borderline signiﬁcance (r = 0.18, P = .05).
Figure 1. Dot plot of intraperson mean capsule size, stratiﬁed by CSF
opening pressure category, n = 122. For the 4 opening pressure categories,
median (IQR) ex vivo capsule sizes were as follows: <20 cm H2O: 5.3
(4.2,5.8) μm; 20–29.9 cm H2O: 5.0 (4.4,5.7) μm, 30–39.9 cm H2O: 5.1
(4.7,5.7) μm and >40 cm H2O: 5.9 (4.9,7.2) μm (Kruskal-Wallis P = .02). The
15 patients with large cells (>5 cells with total diameter >30 μm) are indi-
cated by open symbols. Abbreviations: CSF, cerebrospinal ﬂuid; IQR, inter-
quartile range.
Table 1. Baseline Clinical Variables and CSF Parameters at
Diagnosis
Baseline Variable n Median (IQR)
Males, no. (%) 71 (53%) . . .
Age, years 134 35 (30–40)
CD4 cells/μL 96 16 (6.5–44.5)
Altered mental status, no. (%) 39 (30%) . . .
CSF parameters at initial diagnosis
Opening pressure, cm H2O 124 28.5 (19.6–38.7)
Polymorphs /μL 126 0 (0–5)
Lymphocytes /μL 126 10 (<5–49)
Quantitative C. neoformans
culture (log10 CFU/mL)
130 5.1 (4.32–5.61)
Cryptococcal Antigen
LFA Titer, 1:x
119 8000 (2000–16 000)
CSF GXM exo-polysaccharide
(μg/mL)
38 4.78 (1.28–16.27)
CSF viscosity, ratio to H2O 15 1.11 (1.09–1.27)
Ex vivo CSF cryptococcal cell
measurements
Median (Range)
Total cell diametera, μm 122 16.1 (10.3–29.8)
Capsule sizea,b, μm 122 5.3 (2.9–10.7)
Capsule as % of cell diameter 122 65.1 (52.3–77.4)
% cells budding 118 10 (1–46)
% large cells, total diameter
>30 μm
122 0 (0–44)
Abbreviations: CFU,colony-forming units; CSF, cerebrospinal fluid; GXM,
glucuronoxylomannan; IQR, interquartile range; LFA, lateral flow assay.
a Values derived using intra-patient mean diameters, from measuring 50
yeasts per patient CSF sample.
b Capsule size = (total diameter-cell body diameter)/2.
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Although only 3.6% (441/12 197) of all the cryptococcal cells
measured in human CSF in all subjects at all time points were
large cells (total diameter >30 μm), 15 persons accounted for
80% (352/441) of all the large cells observed. In these subjects,
large cells accounted for up to 62% of all cells measured. The
cell enlargement was due to both capsular (mean size 8.1 μm vs
5.2 μm with and without large cells, P < .001) and cell body en-
largement (mean diameter 8.2 μm vs 5.7 μm, P < 0.001) and
thus not consistent with cryptococcal titan cells observed in
mice (Figure 2) [22, 23]. Those with large cells had higher CSF
CRAG titres compared to those without (median titers
1:14 400 vs 1:8000, P = .03). 13 of 14 with OP recorded had
OP>30 cm H2O, and 9 of 14 (64%) suffered extremely high OP
>40 cm H2O, compared to only 29% in those without large
cells (P = .01; Figure 1, open forms indicate patients with large
cells).
Using CrAg LFA titers, there was no correlation between
ICP and CrAg shedding in CSF (r = − 0.04, P = .67, n = 112). In
the much smaller subset of patients with CSF GXM and CSF
viscosity measurements, there were no signiﬁcant correlations
between ICP and GXM shedding (r =− 0.05, P = .76, n = 37)
nor CSF viscosity (r = 0.17, P = .58, n = 15). There were also no
associations between ICP and in vitro capsule size (P = .59) or
in vitro shedding (P = .31).
Viscosity of GXM Exo-polysaccharide Does Not Differ Between
Normal and High ICP Strains
Figure 3 displays the viscosity of puriﬁed GXM exo-polysaccha-
ride isolated from in vitro culture and diluted in water across
the concentration range 1 μg/mL–10 mg/mL, for 7 clinical C.
neoformans isolates, 4 of which were from persons with raised
ICP (>20 cm H2O, ﬁlled symbols) and 3 with normal ICP
(open symbols). At physiologic concentrations equivalent to
those found in CSF (10−3 mg/mL), high and normal ICP
strains showed no differences in GXM viscosity.
Strains Producing Larger Capsules are Associated With
Paucity of CSF Inﬂammation and Slower Rate of Clearance
From CSF
Average ex vivo capsule size inversely correlated with CSF
WBC count (r =− 0.33, P < .001) and the cytokines IFN-γ
(r = − 0.21, P = .03), IL-4 (r =− 0.23, P = .02), IL-6 (r =− 0.24,
P = .01), IL-7 (r =− 0.20, P = .04), and IL-8 (r =− 0.22,
P = .03). Figure 4 displays the distribution of capsule sizes strat-
iﬁed by presence (WBC ≥5 cells/μL, n = 54) or lack (WBC <5
cells/μL, n = 61) of CSF inﬂammation, with a larger ex vivo
capsule being associated with paucity of inﬂammation (median
4.9 μm among WBC≥5/μL vs 5.5 μm among WBC<5/μL,
P < .001). This was also true for total diameter (median,
15.3 μm vs 17.0 μm; P < .001), largely driven by the increased
capsule size.
An increase in capsule size was associated with a slower rate
of clearance of infection, adjusted for baseline fungal burden.
The EFA for the cohort was −0.34 log10 CFU/mL CSF/day. For
every 1 μm increase in mean capsule size, the EFA decreased by
0.04 CFU/mL CSF/day (SE 0.02, P = .04). In prior studies,
higher levels of IFN-γ were associated with more rapid
Figure 2. Microscopy of CSF (India Ink counterstain, ×40 objective), in a
patient with CSF opening pressure > 55 cm H2O. White arrows indicate
large cells (total diameter > 30 µm), ranging between 30.5 and 41.5 µm in
diameter. Scale bar 10 µm. Abbreviation: CSF, cerebrospinal ﬂuid.
Figure 3. Log-log plot of viscosity (using optical tweezers) vs concen-
tration of puriﬁed GXM exopolysaccharide dissolved in distilled water,
from 7 clinical Cryptococcus neoformans strains [raised ICP (>20 cm H2O)
ﬁlled symbols; normal ICP (≤20 cmH2O) open symbols, isolate ID in
legend]. In all strains, the increase in viscosity with increasing concentra-
tion was non-linear, with viscosity increasing in proportion to the square
root of concentration in the range of 0.02–2 mg/mL (gradient c0.5), and in
proportion to the cube of the concentration in the range of 2–10 mg/mL
(c3), typical of rod-like macromolecules in concentrated solutions [23]. Ab-
breviations: GXM, glucuronoxylomannan; ICP, intracranial pressure.
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clearance of infection [24, 25]. This was not the case in this
cohort, and adjustment for IFN-γ did not alter the association
of capsule size with EFA (coefﬁcient, 0.045; SE = 0.02, P = .04).
There was no signiﬁcant association of capsule size with
CD4 count (P = .59), altered mental status (P = .37) or 2-week
mortality (P = .88).
Intracranial Pressure Remained Associated With Capsular Size
on Multivariable Analysis
On univariate linear regression, CSF parameters signiﬁcantly
associated (P≤ .05) with opening pressure were mean capsule
size, CSF protein, TNF-α, IFN-γ, IL-6, and IL-8. A multivari-
able regression model predicting OP was run using data from
97 patients with complete data for all of these parameters; CSF
fungal burden was also included. Mean capsule size remained
independently associated with CSF OP (β = 2.4, 95% CI: .5–4.2,
P = .01) (Table 2).
Cell and Capsule Parameters Remained Constant Over 2
Weeks’ Antifungal Treatment
Mixed effects models of change in parameters over time were
analyzed among 74 persons with >2 observations over 2 weeks
of antifungal therapy. There were no signiﬁcant changes in cap-
sular size (β =− 0.01, P = .41), cell body diameter (β = − 0.0,
P = .97), or proportion of large cells (β = 0.0, P = .99) over time.
Variables showing signiﬁcant decrease over time, in addition
to fungal burden (mean change −0.31 log10 CFU/mL CSF/day,
P < .001), were CSF OP (mean change −0.62 cmH2O per day,
P = .002), CSF WBC count (−3.4 cells/µL/day, P = .004) and
CSF protein (−0.40 mg/dL per day, P < .001).
Ex Vivo Capsular Phenotype is not Reproducible In Vitro
Induced capsule size in vitro was measured for 58 serial isolates
from 41 patients and compared to ex vivo measurements from
corresponding CSF samples. There was no correlation between
ex vivo and in vitro capsular size (r = − 0.11, P = .4). Mean cap-
sular diameters were larger and more heterogeneous ex vivo
than following in vitro culture in capsule-inducing media,
median (range) 4.7 (0.9–9.5) vs 2.0 (1.1–4.3) μm, respectively.
In addition, no correlation was observed between ex vivo and
in vitro GXM shedding (r = − 0.16, P = .49), even after adjust-
ment for fungal burden in CSF (r =− 0.22, P = .5).
DISCUSSION
To our knowledge, this is the ﬁrst study to examine CSF capsu-
lar phenotype in human cryptococcal meningitis and its rela-
tionship with host clinical and immune parameters. We found
Figure 4. Box plot (median, IQR, 5–95th percentile) of ex vivo mean
capsule size, stratiﬁed by absence or presence of CSF inﬂammation (WBC
≥5 cells/μL), n = 115, P < .001. Persons without a CSF WBC pleocytosis
had Cryptococcus with larger capsules in CSF. Abbreviations: CSF, cerebro-
spinal ﬂuid; IQR, interquartile range; WBC, white blood cell.
Table 2. CSF Parameters Associated With CSF Opening Pressure on Univariate and Multivariable Regression Analysis
Univariate Regression Multivariable Regression
Covariate Coefficienta 95% CI P Value Coefficienta 95% CI P Value
Average capsule size (μm) 2.50 .78, 4.22 .01 2.36 .51, 4.22 .01
Protein (mg/dL) −0.02 −.04, −.003 .02 −0.02 −0.04, .002 .07
TNF-α (log2 pg/mL) −2.29 −4.28, −.29 .03 −2.15 −5.22, .91 .17
IFN-γ (log2 pg/mL) −1.51 −3.05, .02 .05 0.55 −1.83, 2.92 .65
IL-6 (log2 pg/mL) −1.03 −2.00, −.07 .04 0.75 −1.06, 2.57 .41
IL-8 (log2 pg/mL) −2.08 −3.80, −.36 .02 −1.5 −4.62, 1.63 .34
Fungal Burden (log10 CFU/mL) 0.50 −1.98, 2.98 .69 −0.48 −2.94, 1.98 .70
Abbreviations: CI, confidence interval; CFU, colony-forming units; CSF, cerebrospinal fluid; IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.
a Linear regression coefficient is the average change in CSF opening pressure (cm H2O) per 1 unit change in the covariate.
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that persons infected with C. neoformans strains that produced
larger capsules were signiﬁcantly more likely to have raised ICP
at presentation, less CSF inﬂammation, and slower rates of
fungal clearance during treatment with amphotericin B and ﬂu-
conazole.
We have previously shown a relationship between high
fungal burden and raised ICP, such that high fungal burden ap-
peared necessary but not sufﬁcient to produce raised ICP [10].
Although in this cohort fungal burden was not associated with
ICP, it is notable that strains with higher fungal burden at diag-
nosis tended to have larger capsular size (r = 0.19, P = .06).
Based on these ﬁndings, the relationship between capsule size,
paucity of CSF inﬂammation, fungal burden, and raised ICP
seems to be one of inter-related variables with multidirectional
potential interactions, resulting in a particular clinical presenta-
tion (Figure 5).
Average capsular size remained associated with ICP on mul-
tivariable analysis, independent of the other factors. This sup-
ports the hypothesis that cryptococcal capsular phenotype
directly inﬂuences the development of raised ICP in humans,
as suggested in the rat ICP model [16]. This may simply be due
to higher proportions of larger yeasts causing mechanical
outﬂow obstruction in the context of a high fungal burden, sup-
ported by the observation that the 15 persons with highest pro-
portions of large cells almost all developed high ICP.
Conversely, CSF inﬂammation did not appear to drive in-
creased ICP: those with lower concentrations of pro-inﬂamma-
tory cytokines in CSF had higher ICP. In contrast to CM in
HIV-uninfected patients [26, 27], CM in HIV/AIDS is a pauci-
inﬂammatory infection characterized by large fungal burdens.
Cerebral edema is rare on postmortem [11, 28, and 29].
Additionally, corticosteroids, the treatment of cerebral edema,
do not reduce ICP in AIDS-related CM [30].
Differences have been noted in the cell and capsule sizes of
Cryptococcus isolated from diverse organs, such as lung and
brain, observed in both human and mouse studies [31]. In this
study, we necessarily assumed that capsular size in CSF is repre-
sentative of that found in the brain and, speciﬁcally, the arach-
noid villi. A small postmortem study demonstrated highly
encapsulated cryptococci within arachnoid cells, whose
numbers per high power ﬁeld correlated with ICP [11]. The as-
sociation between capsule size in arachnoid cells, fungal
burden, and raised ICP in patients dying of CM needs to be ex-
plored in larger postmortem series.
Strains with larger capsules shed more CrAg, and CrAg titers
correlate with CSF fungal burden [32]; however, CrAg shedding
(by titer or GXM quantiﬁcation) was not associated with raised
ICP. CSF viscosity was also explored as a possible explanation
for increased ICP. Although viscosity increased with fungal
burden, the degree of change was small relative to viscosity of
water. Although GXM exo-polysaccharide is viscous when dis-
solved in water at mg/mL concentrations [33], the conforma-
tion of GXM is relaxed and viscosity decreases in cationic
solutions like CSF. At concentrations <50 µg/mL as found in
rodents [16] and human CSF in our study, GXM is less likely to
disrupt normal CSF mechanics across the arachnoid villi [9],
unless the arachnoid channels act as ﬁlters, with GXM accumu-
lation and polymerization occurring in situ.
GXM is structurally different between strains, which we at-
tempted to study by comparing viscosity of puriﬁed culture su-
pernatants. This revealed similar viscoelastic properties but few
differences between strains, at a range of concentrations in
Figure 5. Schema of proposed inter-relationships between CSF fungal burden, capsule size, CrAg, CSF inﬂammation (WBC count) and raised intracranial
pressure (Correlations shown as positive (+) or negative (−) by Spearman ρ). The arrows show possible directionality of these associations, which interact
to produce mechanical obstruction and raised ICP. An example might be a highly encapsulated strain that elicits less CSF inﬂammation and thus also repli-
cates more effectively, producing higher CSF fungal burden and antigen shedding. The combination of these factors results in raised ICP. Abbreviations:
CrAg, cryptococcal antigen shedding; CSF, cerebrospinal ﬂuid; ICP, intracranial pressure; WBC, white blood cell.
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water. Again, this may not be representative of the in vivo situa-
tion: the conformation of GXM exo-polysaccharide produced
in vitro varies according to the isolation method and differs to
that of bound capsule [34].
In vitro capsular size and shedding showed no correlation
with that of the same strains ex vivo in human CSF, consistent
with the lack of correlation found in mouse brains [14, 35]. In
CSF from this African cohort, poorly encapsulated cells were
rare, unlike some early reports in AIDS patients [36]. Cells and
capsules were larger and far more heterogeneous than in vitro,
consistent with a more evolved, chronic infection [37].
In addition to pathogen factors, there might be host factors
contributing to development of raised ICP, for example, a diffe-
rence in capacity for CSF absorption. This could be further elu-
cidated using CSF outﬂow resistance measurement by lumbar
infusion methods or phase-contrast magnetic resonance
imaging (MRI), techniques that have been successfully applied
in exploring other etiologies of communicating hydrocephalus
[38, 39]. Beyond the arachnoid to dural sinus route, a second
CSF outﬂow route is via lymphatics in perineural and perivas-
cular channels [40]. In this regard it is interesting to note MRI
brain ﬁndings of dilated Virchow-Robin spaces (perivascular
channels ultimately draining into cervical lymph nodes), found
to be full of fungi on postmortem, in 3 CM deaths [41].
Given the lack of in vitro-ex vivo correlations, our study
illustrates the importance, as well as the challenges, of studying the
relative contribution of virulence factors such as the cryptococcal
capsule to clinical presentation in vivo, speciﬁcally in humans
where, unlike in animal models, one is unable to standardize for
host genetic and immune background, fungal inoculum, or timing
of infection. Our ﬁnding of a signiﬁcant independent association
between capsular size and raised ICP, after adjustment for poten-
tial confounders, is thus likely to have pathophysiologic implica-
tions. To show causation, one would need to replicate these
ﬁndings using a selection of highly encapsulated clinical strains,
together with appropriate controls, in the rat ICP model.
In conclusion, we have demonstrated that phenotypic variation
occurs in clinical cryptococcal strains, and that differences in the
in vivo capsule phenotype of infecting C. neoformans strains have
signiﬁcant and important clinical associations. Strains producing
larger capsules were associated with raised ICP as well as poorer
CSF inﬂammatory response and slower rate of fungal clearance.
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